In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Perrigo to bring Merck's Nasonex OTC in the US

Executive Summary

Perrigo Co. PLC licensed exclusive rights to market and distribute a non-prescription version of Merck & Co. Inc.’s nasal spray Nasonex (mometasone) in the US. The treatment is on the market for seasonal/perennial rhinitis, sinusitis, and nasal polyps.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)
    • Reverse Licensing

Related Companies

UsernamePublicRestriction

Register